@article{fdi:010066186,
  title = {{N}ew-onset diabetes and antiretroviral treatments in {HIV}-infected adults in {T}hailand},
  author = {{R}iyaten, {P}. and {S}alvadori, {N}icolas and {T}raisathit, {P}. and {N}go-{G}iang-{H}uong, {N}icole and {C}ressey, {T}. {R}. and {L}eenasirimakul, {P}. and {T}echapornroong, {M}. and {B}owonwatanuwong, {C}. and {K}antipong, {P}. and {N}ilmanat, {A}. and {Y}utthakasemsunt, {N}. and {C}hutanunta, {A}. and {T}hongpaen, {S}. and {K}linbuayaem, {V}. and {D}ecker, {L}uc and {L}e {C}oeur, {S}. and {L}allemant, {M}arc and {C}apeau, {J}. and {M}ary, {J}. {Y}. and {J}ourdain, {G}onzague},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {U}se of several antiretrovirals ({ARV}s) has been shown to be associated with a higher risk of diabetes in {HIV}-infected adults. {W}e estimated the incidence of new-onset diabetes and assessed the association between individual {ARV}s and {ARV} combinations, and diabetes in a large cohort in {T}hailand. {M}ethods: {W}e selected all {HIV}-1-infected, nondiabetic, antiretroviral-naive adults enrolled in the {P}rogram for {HIV} {P}revention and {T}reatment cohort ({NCT}00433030) between {J}anuary 2000 and {D}ecember 2011. {D}iabetes was defined as confirmed fasting plasma glucose >= 126 mg/d{L} or random plasma glucose >= 200 mg/d{L}. {I}ncidence was the number of cases divided by the total number of person-years of follow-up. {A}ssociation between {ARV}s and {ARV} combinations, and new-onset diabetes was assessed using {C}ox proportional hazards models. {R}esults: {O}verall, 1594 {HIV}-infected patients (76% female) were included. {M}edian age at antiretroviral therapy initiation was 32.5 years. {T}he incidence rate of diabetes was 5.0 per 1000 person-years of followup (95% confidence interval: 3.8 to 6.6) (53 cases). {I}n analyses adjusted for potential confounders, exposure to stavudine + didanosine [adjusted hazard ratio (a{HR}) = 3.9; {P} = 0.001] and cumulative exposure >= 1 year to zidovudine (a{HR} = 2.3 vs. no exposure; {P} = 0.009) were associated with a higher risk of diabetes. {C}onversely, cumulative exposure >= 1 year to tenofovir (a{HR} = 0.4 vs. no exposure; {P} = 0.02) and emtricitabine (a{HR} = 0.4 vs. no exposure; {P} = 0.03) were associated with a lower risk. {C}onclusions: {T}he incidence of diabetes in this predominantly female, young, lean population was relatively low. {A}lthough stavudine and didanosine have now been phased out in most antiretroviral therapy programs, our analysis suggests a higher risk of diabetes with zidovudine, frequently prescribed today in resource-limited settings.},
  keywords = {{HIV} ; diabetes ; incidence ; {NRTI}s ; tenofovir ; zidovudine ; {THAILANDE}},
  booktitle = {},
  journal = {{JAIDS} : {J}ournal of {A}cquired {I}mmune {D}eficiency {S}yndromes},
  volume = {69},
  numero = {4},
  pages = {453--459},
  ISSN = {1525-4135},
  year = {2015},
  DOI = {10.1097/qai.0000000000000647},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066186},
}